Skip to main content
OpenTrials

Clinical trial condition

Lung Diseases, Obstructive

Explore clinical trials studying Lung Diseases, Obstructive. Study availability and eligibility vary by location and protocol.

7,975 public trials 742 recruiting studies
Refine in advanced search Browse all conditions

Lung Diseases, Obstructive trial results

Completed

Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)

NCT00163462

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • Altana Pharma/Nycomed Campinas - SP, Brazil
  • Altana Pharma/Nycomed Curitiba-PR, Brazil
  • Altana Pharma/Nycomed Florianópolis-SC, Brazil
  • Altana Pharma/Nycomed Porto Alegre-RS, Brazil
View all 57 locations
View Trial Details
Completed

Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)

NCT00242320

Conditions
COPD, Chronic Disease, Disease Attributes, +6 more
Locations
  • Altana Pharma/Nycomed Hong Kong
  • Altana Pharma/Nycomed Shatin, NT, Hong Kong, Hong Kong
  • Altana Pharma/Nycomed Jalan Rasah, Seremban, Malaysia
  • Altana Pharma/Nycomed Kota Bharu / Kelantan, Malaysia
View all 32 locations
View Trial Details
Completed

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

NCT00076089

Conditions
COPD, Chronic Disease, Chronic Obstructive Pulmonary Disease, +7 more
Locations
  • ALTANA Pharma Cities in Alabama, Alabama, United States
  • ALTANA Pharma Cities in Arizona, Arizona, United States
  • ALTANA Pharma Cities in Arkansas, Arkansas, United States
  • ALTANA Pharma Cities in California, California, United States
View all 40 locations
View Trial Details
Completed

The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

NCT00076076

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • ALTANA Pharma Cities in Alabama, Alabama, United States
  • ALTANA Pharma Cities in Arizona, Arizona, United States
  • ALTANA Pharma Cities in Arkansas, Arkansas, United States
  • ALTANA Pharma Cities in California, California, United States
View all 41 locations
View Trial Details
Completed

Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

NCT00163527

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • ALTANA Pharma Cities in Georgia, Georgia, United States
  • ALTANA Pharma Cities in Austria, Austria
  • ALTANA Pharma Cities in Croatia, Croatia
  • ALTANA Pharma Cities in the Czech Repulik, Czechia
View all 24 locations
View Trial Details
Completed

Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)

NCT00163319

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • Altana Pharma/Nycomed Brussels, Belgium
  • Altana Pharma/Nycomed Brussels, Belgium
  • Altana Pharma/Nycomed Brussels, Belgium
  • Altana Pharma/Nycomed Halen, Belgium
View all 89 locations
View Trial Details
Completed

Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205)

NCT00163410

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • Altana Pharma/Nycomed Ahmedabad, India
  • Altana Pharma/Nycomed Bangalore, India
  • Altana Pharma/Nycomed Chandigarh, India
  • Altana Pharma/Nycomed Coimbatore, India
View all 16 locations
View Trial Details
Completed

A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01319019

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Tallinn, Estonia
  • GSK Investigational Site Tallinn, Estonia
  • GSK Investigational Site Tallinn, Estonia
  • GSK Investigational Site Tartu, Estonia
View all 49 locations
View Trial Details

Related conditions